Events
BIO International
Join Vibe Bio at the BIO International Convention
Join us at the largest and most comprehensive event for biotechnology. Held at the Boston Convention & Exhibition Center from June 16-19, it will represent the full ecosystem of biotech with 20,000 industry leaders from across the globe.
Webinar On Demand
Bottlenecks to breakthroughs: How AI is reshaping biopharma BD&L
Biopharma BD&L and search & evaluation teams are the front lines to identifying and advancing new assets and platforms that shape a company’s pipeline. Their work is diverse: from competitive benchmarking and program assessment to commercial forecasting, all while tracking the explosion of global pharmaceutical innovation.
Additional resources
Jay Andersen, a pioneer in pharmaceutical decision-making, shared some lessons learned from developing portfolio management and probability assessment approaches.
Founding Members Chiesi, BIAL Lead Initial Funding; Landmark Bio, Uncommon Cures Join Clinical Development Network; DVLP Medicines, Vibe Bio to Provide Integrated AI-based Solutions
Pharma's business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company's future. As the biopharma industry navigates an increasingly complex marketplace, traditional approaches to identifying and evaluating potential drug candidates are showing signs of strain.
Biopharma business development and scientific teams are under a lot of pressure to identify the next big program for their indication and strategy.
I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.
